WE ARE IN IT TO WIN IT!
Guzzo Nano Research aims to exploit the properties of nanoparticles to develop novel technologies that would improve health outcomes.
OUR RESEARCH
ABOUT THE FOUNDATION
The Guzzo Family Foundation fervently supports cancer nanotechnology research at two esteemed institutions: Montreal's Jewish General Hospital and McGill University. Their investment in this cutting-edge field aims to unravel the mysteries of cancer at the nano level, seeking breakthroughs that could transform diagnosis, treatment, and patient outcomes.
​
​In the halls of research labs, where molecules dance and hope takes shape, the Guzzo Family Foundation leaves an indelible footprint—a testament to their unwavering commitment to humanity's well-being. Cancer, once a formidable adversary, now faces a formidable alliance: the convergence of science, compassion, and the Guzzo legacy.
OUR TEAM
Vincenzo Guzzo
President
As the president and CEO of Cinémas Guzzo, Vincenzo oversees the largest movie operator in Quebec, boasting 141 screens and 10 locations. Cinémas Guzzo ranks as the third-largest movie operator in Canada. The company was originally founded by his father, Angelo Guzzo, who remains the chairman of the board. Vincenzo's involvement in the business began when he worked as an usher and gradually took on more responsibilities.
​
Vincenzo and his family actively contribute to charitable causes through the Guzzo Family Foundation. Their efforts have been recognized, and Vincenzo received the Queen Elizabeth II Diamond Jubilee Medal in 2012. He was also knighted by the Order of Merit of the Italian Republic and is a member of the Order of Malta
Miltiadis Paliouras
Ph.D., Vice President,
Scientific Director
Dr. Miltiadis Paliouras is an Assistant Professor in the Department of Medicine, specifically the Division of Experimental Medicine at McGill University. He is also an Associate Member of the Gerald Bronfman Department of Oncology at McGill. Dr. Paliouras has an impressive academic background, having completed a Bachelor’s degree at the University of Toronto, a Master’s degree at the University of Florida, and a PhD at McGill.
Nadia Nour
Ph.D., Business Development Director
Mark Trifiro
M.D., Medical Director
Nadia Nour's involvement in Guzzo Nano Research Corporation contributes to the advancement of scientific exploration and technological breakthroughs.
Mark Trifiro is a researcher and scientist who has made significant contributions in the field of photothermal therapy for prostate cancer. His work focuses on utilizing nanoparticles, specifically multiwalled carbon nanotubes (MWCNTs), for precise tumor ablation.
Michael Tamilia
M.D., Stakeholder
Dr. Michael Tamilia is an accomplished endocrinologist based in Montreal. He holds the position of Assistant Professor in the Department of Otolaryngology – Head and Neck Surgery at McGill University. Dr. Tamilia's expertise lies in the management of thyroid cancer. He is also the Director of the Thyroid Center at the Jewish General Hospital. His dedication to patient care and research makes him a valuable asset in the field of endocrinology
PATENTS
& LICENSES
BIONANOFLUID FOR USE AS A CONTRAST, IMAGING, DISFECTING AND/OR THERAPEUTIC AGENT
Patents filed in Canada, US, and Europe
USPTO Notice of Allowance – 2018
CIPO Notice of Award – 2022
EPO Under prosecution
In 2022 GNR secured a license, with an assignment option, for the nanotherapeutics technology from McGill University.
OUR
PARTNERS
FINANCING & INVESTMENTS
GNR and its scientific colleagues have invested over $1.3 million (CAD), with over $315K from GNR directly, into the development of the BioNanofluid, through various academic and private-public-partnership funding programs.
Specific financing has been in the form of:
GNR financially sponsored, a grant that was awarded to Drs. Trifiro and Paliouras from PRIMA Quebec ($462,502). Part of the grant is also sponsored by, MITACS, The Jewish General Hospital Foundation and Institute TransMedTech. The grant would explore the application of Raman Spectroscopy as an imaging modality to assess the concentration of the Nanoformulation at the tumor site. Knowing how much Nanoformulation accumulates at the tumor site, will determine the power and duration of laser exposure, and thus ensure complete tumor ablation.
​
With GNR’s financial partnership, Drs. Trifiro and Paliouras, are awarded a PSO grant from the Ministre de Innovation et Education ($183,000). This grant would assess the efficacy of the TSHR-BioNanofluid in an animal tumor model.
GNR, in partnership with Neovaltech, were awarded a Bon d’Incubation grant ($38,850) form the Ministre de Innovation et Education. This grant provided consultation services with Health Canada and allowed for the definition of the Nanoformulation as a medical device. The designation of the Nanoformulation as a medical device would significantly determine the scope of the clinical trials moving forward.
PUBLICATIONS
CONFERENCE PROCEEDINGS
& ABSTRACTS
Pre-clinical demonstration of Raman spectroscopy-assisted photothermal therapy for prostate cancer
​
Lee SS, Beaudoin G, Yeoh J, Leblond F, Trifiro M, Paliouras M. Pre-clinical demonstration of Raman spectroscopy-assisted photothermal therapy for prostate cancer, 2024 AACR Annual Meeting, San Diego, CA, April 5-10, 2024
Development of HER2-targeted photothermal immunotherapy using multiwalled carbon nanotubes,
​
Lee SS, Oudjedi F, Kirk A, Paliouras M, Trifiro M. Development of HER2-targeted photothermal immunotherapy using multiwalled carbon nanotubes, 8th Nano Today Conference, San Diego, CA, April 22-25, 2023
​TSHR targeting Multi-walled Carbon Nanotubes for Precision Photothermal Therapy
Lee SS*, Trifiro MA, Paliouras M. TSHR targeting Multi-walled Carbon Nanotubes for Precision Photothermal Therapy. NanoCanada – From Earth to Space. Edmonton, Canada, June 8-10, 2022 selected for oral presentation
Development of Bio-affinity Nanoparticles: Applications for Cancer Imaging and Therapeutics
Lee S, Roche PJR, Dotan I, Carnevale M, Mitmaker E, Trifiro MA, Paliouras M. Development of Bio-affinity Nanoparticles: Applications for Cancer Imaging and Therapeutics. Canadian Cancer Research Conference, Montreal QC, Canada
Synthesis of Conjugated Nanoparticles to Target Papillary Thyroid Cancer In Vitro
Dotan I, Paliouras M, Roche PJR, Beitel LK, Tamilia M, Trifiro MA, Mitmaker EJ, Synthesis of Conjugated Nanoparticles to Target Papillary Thyroid Cancer In Vitro. American Association of Endocrine Surgeons Annual Meeting, Nashiville TN, USA
Development of Bio-affinity Nanoparticles: Applications for Cancer Imaging and Therapeutics
Dotan I, Roche PJR, Mitmaker E, Trifiro MA, Paliouras M. Development of Bio-affinity Nanoparticles: Applications for Cancer Imaging and Therapeutics. 2015 AACR Annual Conference, Philadelphia, PA, USA
Engineering BioNanofluids to Target Papillary Thyroid Cancer Cell Lines
Dotan I, Mitmaker E, Roche PJR, Beitel LK, Tamilia M, Trifiro MA, Paliouras M. Engineering BioNanofluids to Target Papillary Thyroid Cancer Cell Lines. 2015 ENDO Society Conference, San Diego, CA, USA
Engineering BioNanofluids to Target Papillary Thyroid Cancer Cell Lines
Dotan I, Mitmaker E, Roche PJR, Beitel LK, Tamilia M, Trifiro MA, Paliouras M. Engineering BioNanofluids to Target Papillary Thyroid Cancer Cell Lines. 2015 Canadian Society of Endocrinology and Metabolism, Winnepeg, MB, Canada